Chimerix (NASDAQ:CMRX) Stock Price Crosses Below 200 Day Moving Average of $1.00

Chimerix, Inc. (NASDAQ:CMRX) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.00 and traded as low as $0.90. Chimerix shares last traded at $0.91, with a volume of 506,516 shares changing hands.

Analyst Ratings Changes

CMRX has been the subject of several recent research reports. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a report on Monday, March 4th. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Chimerix in a research note on Friday, March 1st. Finally, Wedbush restated an “outperform” rating and set a $6.00 target price on shares of Chimerix in a research note on Monday, February 12th.

Chimerix Price Performance

The stock’s fifty day simple moving average is $1.08 and its 200-day simple moving average is $1.00. The stock has a market cap of $81.59 million, a P/E ratio of -0.99 and a beta of 1.15.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 37.93%. Analysts forecast that Chimerix, Inc. will post -0.77 EPS for the current year.

Institutional Investors Weigh In On Chimerix

A number of hedge funds have recently made changes to their positions in CMRX. Swiss National Bank raised its holdings in shares of Chimerix by 8.8% during the first quarter. Swiss National Bank now owns 174,600 shares of the biopharmaceutical company’s stock valued at $800,000 after buying an additional 14,100 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Chimerix by 22.4% during the first quarter. JPMorgan Chase & Co. now owns 46,616 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 8,519 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Chimerix by 56.2% during the first quarter. MetLife Investment Management LLC now owns 42,753 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 15,374 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Chimerix by 11.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,951,521 shares of the biopharmaceutical company’s stock valued at $8,938,000 after buying an additional 206,990 shares during the last quarter. Finally, Cetera Investment Advisers bought a new stake in shares of Chimerix during the first quarter valued at approximately $77,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.